News

Video

Angiogenesis 2024: AVD-104 for Geographic Atrophy

Author(s):

Martin David Harp
Conferences|Angiogenesis

Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.

Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191
June 26th 2025

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001
June 25th 2025

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001

(Image credit: AdobeStock/WS Studio 1985)
June 25th 2025

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

© 2025 MJH Life Sciences

All rights reserved.